Search - tctmd.com

Displaying 1 - 20 of 511

Sort: Relevancy | Date

Presentation

TAVR in Pure Native Aortic Valve Regurgitation (AR)

November 30, 2017

Presentation Cardiovascular Interventions 2017

How Me The Data: Key Clinical Trials of 2017

Presenter: Curtiss T. Stinis

November 09, 2017

Presentation Cardiovascular Interventions 2017

TAVR Tips and Tricks: How to Succeed with Challenging Cases

Presenter: Curtiss T. Stinis

November 08, 2017

Presentation TCT 2017

FORMA: 30-Day Outcomes of Transcatheter TV Repair in Patients With Severe Secondary Tricuspid Regurgitation

Presenter: Martin B. Leon, Susheel K. Kodali

November 02, 2017

Presentation TCT 2017

TRI-REPAIR: 30-Day Outcomes of Transcatheter TV Repair in Patients With Severe Secondary Tricuspid Regurgitation

Presenter: Martin B. Leon, Georg Nickenig

November 02, 2017

Presentation TCT 2017

Adjunctive Pharmacotherapy During and After TAVR: Current Trends, New Studies, and the Case for Short-term (3-6 months) Systemic Anticoagulation

Presenter: Eberhard Grube, James B. Hermiller Jr., Pascal Vranckx

November 01, 2017

Presentation TCT 2017

A Primer of Conduction Abnormalities after TAVR: Frequency, Clinical Consequences, and Revised Management Recommendations (New Permanent Pacemakers)

Presenter: Eberhard Grube, James B. Hermiller Jr., Hemal Gada

November 01, 2017

Presentation TCT 2017

Hemodynamic Trends on Serial Echocardiograms after TAVR: Comprehensive 5-Year Analyses From PARTNER

Presenter: Pamela S. Douglas

November 01, 2017

Presentation TCT 2017

Valve Durability after TAVR: Definitions, Surgical Valve Predicates, and Review of Available Data

Presenter: Danny Dvir

November 01, 2017

Presentation TCT 2017

The Clinical Relevance of Valve Leaflet Thickening after TAVR

Presenter: Raj Makkar

November 01, 2017

Presentation TCT 2017

Underutilization of TAVR in Minority Populations: Scope, Etiologies, and Possible Solutions

Presenter: Eberhard Grube, James B. Hermiller Jr., Oluseun Alli

November 01, 2017

Presentation TCT 2017

Shared Decision-making is an Essential Component of the Modern-era Heart Team: Rationale and Integration with TAVR Clinical Practice

Presenter: Eberhard Grube, James B. Hermiller Jr., Megan Coylewright

November 01, 2017

Presentation TCT 2017

Counterpoint More than Two TAVR Devices on Your Shelf is Unnecessary!

Presenter: Haim Danenberg

November 01, 2017

Presentation TCT 2017

30-Day Outcomes of Transcatheter MV Replacement in Patients With Severe Mitral Valve Disease Secondary to Mitral Annular Calcification or Failed Annuloplasty Rings

Presenter: Mayra Guerrero

November 01, 2017

Presentation TCT 2017

Point A Multi-Device Lesion-Specific Approach is Preferred!

Presenter: Michael J. Reardon

November 01, 2017

Presentation TCT 2017

Commentary II At What Point Does the Minimalist Strategy Become Ludicrous?

Presenter: Martin B. Leon

November 01, 2017

Presentation TCT 2017

Commentary I Insights From the 3M Trial

Presenter: David A. Wood

November 01, 2017

Presentation TCT 2017

Counterpoint A Customized Approach, Including General Anesthesia and TEE, Optimizes Patient Outcomes!

Presenter: Omar K. Khalique

November 01, 2017

Presentation TCT 2017

Point TAVR Without General Anesthesia and Without TEE is now the Default Strategy!

Presenter: Ganesh Manoharan

November 01, 2017

Presentation TCT 2017

Case #1: A Dreaded TAVI Complication

Presenter: Amal Kumar Banerjee, Purvez K Grant, Nagendra Singh Chouhan

November 01, 2017

Advertisement

TAVR in Pure Native Aortic Valve Regurgitation (AR)

How Me The Data: Key Clinical Trials of 2017

TAVR Tips and Tricks: How to Succeed with Challenging Cases

FORMA: 30-Day Outcomes of Transcatheter TV Repair in Patients With Severe Secondary Tricuspid Regurgitation

TRI-REPAIR: 30-Day Outcomes of Transcatheter TV Repair in Patients With Severe Secondary Tricuspid Regurgitation

Adjunctive Pharmacotherapy During and After TAVR: Current Trends, New Studies, and the Case for Short-term (3-6 months) Systemic Anticoagulation

A Primer of Conduction Abnormalities after TAVR: Frequency, Clinical Consequences, and Revised Management Recommendations (New Permanent Pacemakers)

Hemodynamic Trends on Serial Echocardiograms after TAVR: Comprehensive 5-Year Analyses From PARTNER

Valve Durability after TAVR: Definitions, Surgical Valve Predicates, and Review of Available Data

The Clinical Relevance of Valve Leaflet Thickening after TAVR

Underutilization of TAVR in Minority Populations: Scope, Etiologies, and Possible Solutions

Shared Decision-making is an Essential Component of the Modern-era Heart Team: Rationale and Integration with TAVR Clinical Practice

Counterpoint More than Two TAVR Devices on Your Shelf is Unnecessary!

30-Day Outcomes of Transcatheter MV Replacement in Patients With Severe Mitral Valve Disease Secondary to Mitral Annular Calcification or Failed Annuloplasty Rings

Point A Multi-Device Lesion-Specific Approach is Preferred!

Commentary II At What Point Does the Minimalist Strategy Become Ludicrous?

Commentary I Insights From the 3M Trial

Counterpoint A Customized Approach, Including General Anesthesia and TEE, Optimizes Patient Outcomes!

Point TAVR Without General Anesthesia and Without TEE is now the Default Strategy!

Case #1: A Dreaded TAVI Complication

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content